Literature DB >> 35168706

Antiviral Therapeutics in Pediatric Transplant Recipients.

William R Otto1, Abby Green2.   

Abstract

Recipients of solid organ and hematopoietic stem cell transplantation undergo substantial immune suppression, placing them at risk for opportunistic viral infection. Few randomized controlled trials have been dedicated to the treatment of viral infections in children, and current practices are extrapolated from data generated from adult patients. Here we discuss the prevention and treatment of viral infections using available antiviral drugs, as well as novel agents that may provide benefit to pediatric patients in the future.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antiviral; Hematopoietic stem cell transplant; Herpesvirus; Immunocompromised host; Pediatrics; Solid organ transplant; Viral infection

Mesh：

Substances：

Year:  2022        PMID： 35168706      PMCID： PMC8900721          DOI： 10.1016/j.idc.2021.11.004

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN： 0891-5520            Impact factor:   5.982


  89 in total

1.  Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir in allogeneic stem cell transplant patients with graft-versus-host disease of the gastrointestinal tract.

Authors:  Drew J Winston; Lindsey R Baden; Don A Gabriel; Christos Emmanouilides; Leslie M Shaw; W Robert Lange; Voravit Ratanatharathorn
Journal:  Biol Blood Marrow Transplant       Date:  2006-06       Impact factor: 5.742

2.  Outcomes in Transplant Recipients Treated With Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection.

Authors:  Robin K Avery; Ravit Arav-Boger; Kieren A Marr; Edward Kraus; Shmuel Shoham; Laura Lees; Brandon Trollinger; Pali Shah; Rich Ambinder; Dionysios Neofytos; Darin Ostrander; Michael Forman; Alexandra Valsamakis
Journal:  Transplantation       Date:  2016-10       Impact factor: 4.939

3.  Definitions of Resistant and Refractory Cytomegalovirus Infection and Disease in Transplant Recipients for Use in Clinical Trials.

Authors:  Roy F Chemaly; Sunwen Chou; Hermann Einsele; Paul Griffiths; Robin Avery; Raymund R Razonable; Kathleen M Mullane; Camille Kotton; Jens Lundgren; Takashi E Komatsu; Peter Lischka; Filip Josephson; Cameron M Douglas; Obi Umeh; Veronica Miller; Per Ljungman
Journal:  Clin Infect Dis       Date:  2019-04-08       Impact factor: 9.079

4.  Long-term impact of respiratory viral infection after pediatric lung transplantation.

Authors:  M Liu; G B Mallory; M G Schecter; S Worley; S Arrigain; J Robertson; O Elidemir; L A Danziger-Isakov
Journal:  Pediatr Transplant       Date:  2010-03-04

5.  Delay of alternative antiviral therapy and poor outcomes of acyclovir-resistant herpes simplex virus infections in recipients of allogeneic stem cell transplant - a retrospective study.

Authors:  Ella J Ariza-Heredia; Roy F Chemaly; Lokesh R Shahani; Ying Jang; Richard E Champlin; Victor E Mulanovich
Journal:  Transpl Int       Date:  2018-03-13       Impact factor: 3.782

6.  Herpes simplex virus infections in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.

Authors:  Dong H Lee; Richard A Zuckerman
Journal:  Clin Transplant       Date:  2019-04-11       Impact factor: 2.863

7.  Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation.

Authors:  Pierre Reusser; Hermann Einsele; John Lee; Liisa Volin; Montserrat Rovira; Dan Engelhard; Jürgen Finke; Catherine Cordonnier; Hartmut Link; Per Ljungman
Journal:  Blood       Date:  2002-02-15       Impact factor: 22.113

8.  Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation.

Authors:  Francisco M Marty; Per Ljungman; Roy F Chemaly; Johan Maertens; Sanjeet S Dadwal; Rafael F Duarte; Shariq Haider; Andrew J Ullmann; Yuta Katayama; Janice Brown; Kathleen M Mullane; Michael Boeckh; Emily A Blumberg; Hermann Einsele; David R Snydman; Yoshinobu Kanda; Mark J DiNubile; Valerie L Teal; Hong Wan; Yoshihiko Murata; Nicholas A Kartsonis; Randi Y Leavitt; Cyrus Badshah
Journal:  N Engl J Med       Date:  2017-12-06       Impact factor: 91.245

9.  Current practices for treatment of respiratory syncytial virus and other non-influenza respiratory viruses in high-risk patient populations: a survey of institutions in the Midwestern Respiratory Virus Collaborative.

Authors:  O E Beaird; A Freifeld; M G Ison; S J Lawrence; N Theodoropoulos; N M Clark; R R Razonable; G Alangaden; R Miller; J Smith; J A H Young; D Hawkinson; K Pursell; D R Kaul
Journal:  Transpl Infect Dis       Date:  2016-03-29       Impact factor: 2.228

10.  Respiratory viral infections within one year after pediatric lung transplant.

Authors:  M Liu; S Worley; S Arrigain; P Aurora; M Ballmann; D Boyer; C Conrad; I Eichler; O Elidemir; S Goldfarb; G B Mallory; P J Mogayzel; D Parakininkas; G Visner; S Sweet; A Faro; M Michaels; L A Danziger-Isakov
Journal:  Transpl Infect Dis       Date:  2009-05-03       Impact factor: 2.228
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.